<DOC>
	<DOCNO>NCT02676401</DOCNO>
	<brief_summary>This study aim evaluate safety efficacy MT-3995 administer long term , follow MT-3995-J05 study .</brief_summary>
	<brief_title>An Extended Treatment Study MT-3995 Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Written inform consent participation completion MT3995J05 Study Completion MT3995J05 study UACR ≥300 mg/g Cr increase ≥30 % MT3995J05 Study Symptomatic clinically significant hypotension QT prolongation torsades de point New York Heart Association ( NYHA ) Class III IV heart failure Patients judge unsuitable participation base safety profile MT3995J05 Study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>